Lunes, 06 Diciembre 2010 14:09

China fights growing problem of tuberculosis

Guangzhou, 06 Jan 2010 - China, saddled with the world's second largest tuberculosis burden after India, is fighting an uphill battle against drug-resistant forms of the disease which will only drain the country's health budget.

Drug-resistant TB, far more expensive to treat, emerges when patients fail to follow treatment regimens and take substandard drugs or stop treatment too early.

Liu Zhongwu, a stonecutter working in southern China, for example, stopped taking his TB medication midway through a standard six-month course in 2007 because it was too costly.

"Even though one or two drugs were free, I had to pay 500 yuan ($73) a month for other drugs (to reduce side effects) and the side effects were bad, I suffered terrible gastric pain and had to stop work, I didn't even have energy to walk," said Liu.

It is precisely this sort of behavior that health experts are trying to stop because if the TB bacteria is not fully eliminated, it can mutate, resurge later and become resistant to the small arsenal of drugs that can fight the disease.

China has 4.5 million TB cases currently; and each year 1.4 million people fall ill with the disease. TB killed 160,000 people in China in 2008, according to the World Health Organization.

TB killed 1.8 million people across the world in 2008, or a person every 20 seconds. It is not only a scourge in poor countries but also in the West, where it has flared anew in the last 20 years because of AIDS, which weakens the immune system.


TB is also a big drain on China's health budget because of a high incidence of people with a drug-resistant strain of the disease, which is a lot harder and more expensive to treat.

In such cases, patients need to take drugs for up to two years and the worst type of TB, for which there is no cure, kills one out of every two patients.

"If there are more drug-resistant cases, the cost of TB treatment will rise by a lot, that's for sure. With drug resistance, we can't use first-line drugs and other drugs cost a lot more," said Lin Yan, director of the China office of the non-profit International Union Against TB and Lung Disease.

"When these patients infect others, the others will get drug-resistant TB. That increases the cost of treating that person and increases the chances of him not recovering."

Regular TB costs 1,000 yuan to treat in China but drug-resistant TB ranges from 100,000 to 300,000 yuan per person, said Zhong Qiu of China's TB Expert Consultative Committee.

China ranks second in the world with 112,000 drug-resistant TB cases in 2007, after India with 131,000. Russia has 43,000 cases, while South Africa has 16,000 and Bangladesh 15,000.

China spent $225 million on tackling TB in 2008, up from $98 million in 2002, according to WHO. These figures do not take into account what patients pay out of their pockets, typically between 47 and 62 percent of their hospital bills.

Drug-resistant TB made up 27.8 percent of all TB cases in China in 2000 versus five percent in advanced countries.

"There are many reasons for China's drug-resistant TB problem. Patients stop taking drugs when they feel better, maybe after a month. Some have no money for drugs if the treatment is not free and they don't even know this is a serious disease," said Lin.

"Some are so afraid of stigma they don't see a doctor, they just buy drugs over the counter."


TB affects mostly poor people, who typically live in places where healthcare is not easily accessible. Many patients pay not only for treatment but also transportation, and any chronic, long-term disease can bankrupt entire families.

Li Jiachuen, 45, quickly ran out of money and had to borrow from relatives and friends after he was diagnosed with TB.

"I don't take drugs now. I don't even have money to pay off my 20,000 yuan debt. I spent thousands of yuan on diagnosis and treatment and even more on transportation," Li said.

WHO recommends all TB treatment be free because the disease is a public health threat.

But in China, diagnosis and treatment is only free in specialist TB outpatient clinics. General hospitals, which have been self-financing since the 1990s, impose charges.

"TB is a political problem because it is infectious. It has societal impact, it is a threat to public health ... free treatment is very important," said Zhong, who also heads the Anti-TB Research Institute in China's southern Guangdong province.

The world's only TB vaccine is 100 years old and there has been no new TB drug for more than 40 years. But the resurgence of TB due to AIDS has forced the West back into TB research in the last 20 years and a string of experimental drugs and vaccines are now in the pipeline.

Chinese scientists are working on a new class of TB drugs based on an old drug called clofazimine, used in the past to treat leprosy, said Ann Ginsberg, chief medical officer of the TB Alliance, a US-based non-profit scientific group that pulls together partners to develop new TB drugs.

"They (scientists) found a very promising lead compound and we hope within the next six months ... it will come into formal pre-clinical development and get the formal animal and non human studies that are required to convince the regulators it can go onto people," said Ginsberg.

Lunes, 06 Diciembre 2010 13:57

Global Plan to Stop TB 2006-2015 and related information

The implementation of the US$ 56 billion Plan will result in:

  • Implementation of the Stop TB Strategy will expand equitable access for all to quality TB diagnosis and treatment.
  • Over the ten years of this Plan, about 50 million people will be treated for TB under the Stop TB Strategy, including about 800 000 patients with MDR-TB, and about 3 million patients who have both TB and HIV will be enrolled on antiretroviral therapy (ART).
  • Some 14 million lives will be saved from 2006 to 2015.
  • The first new TB drug for 40 years will be introduced in 2010, with a new short TB regimen (1-2 months) shortly after 2015.
  • By 2010, diagnostic tests at the point of care will allow rapid, sensitive and inexpensive detection of active TB. By 2012, a diagnostic toolbox will accurately identify people with latent TB infection and those at high risk of progression to disease.
  • By 2015 a new, safe, effective and affordable vaccine will be available with potential for a significant impact on TB control in later years.

ICN supports the Global Plan and encourages people to read the document. You can find the full text on

You can find more information on the Global To Stop TB 2006-15 on

The Stop TB Strategy and the WHO Report 2006 Global Tuberculosis Control: surveillance, planning, financing can be downloaded on

Lunes, 14 Junio 2010 15:25







Viernes, 04 Junio 2010 07:49

2010 TB Award Recipients

Twelve Nurses win the 4th ICN/Lilly Award  for Work in Tuberculosis and Multi-drug Resistant TB

The ICN/Lilly Award for Nursing Excellence in TB/MDR-TB is one aspect of ICN’s work in TB and multi-drug resistant TB as a founding member of the Lilly MDR-TB Partnership. Through this Partnership more than 18 000 nurses have been trained in TB endemic countries. This annual award supported by Lilly recognizes nursing expertise and aims to motivate and recognise nurses working with those affected by TB and MDR-TB in countries included in the TB project. It showcases the contribution made by nurses to TB prevention, care and treatment and offers the recipients an educational grant to continue their professional development along with a specially designed medal. Recipients are selected by their national nurses association for their outstanding achievement in TB prevention, care and treatment.

On the occasion of World TB Day, the International Council of Nurses in partnership with Eli Lilly and Company has given awards to the following nurses, from eleven countries, who through their dedication, passion and innovative care strategies, are living examples of the World TB Day slogan "On the move against tuberculosis: innovate to accelerate action".

Lunes, 08 Marzo 2010 13:35

2007 TB Award Recipients

Five Nurses Win the Newly Launched ICN/Lilly Award for Work in Tuberculosis and Multi–drug Resistant TB.

Lunes, 08 Marzo 2010 13:34

2008 TB Award Recipients

Eleven Nurses Win the 2nd ICN/Lilly  Award for Work in Tuberculosis and Multi–drug Resistant TB

On the occasion of World TB Day, the International Council of Nurses (ICN), in partnership with Eli Lilly and Company, conferred special awards to nurses working on the ground in fighting the scourge of tuberculosis (TB) and multi-drug resistant TB. The 2008 award recipients come from six TB affected countries: Kenya, Lesotho, Malawi, the Russian Federation, South Africa and Swaziland.

Lunes, 08 Marzo 2010 13:29

2009 TB Award Recipients

Eleven Nurses win the 3rd ICN/Lilly Award for Work in Tuberculosis and Multi-drug Resistant TB

On the occasion of World TB Day, the International Council of Nurses (ICN), in partnership with Eli Lilly and Company, conferred special awards to the following nurses who have demonstrated exceptional dedication to the fight against the scourge of tuberculosis (TB) in their countries.

Página 4 de 4